| pubmed-article:20404974 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20404974 | lifeskim:mentions | umls-concept:C0019994 | lld:lifeskim |
| pubmed-article:20404974 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:20404974 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:20404974 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:20404974 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:20404974 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:20404974 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20404974 | pubmed:dateCreated | 2010-4-20 | lld:pubmed |
| pubmed-article:20404974 | pubmed:abstractText | Based on the TAX 327 phase III trial, docetaxel-based chemotherapy is the standard first-line treatment for hormone-resistant prostate cancer (HRPC); however, there is some heterogeneity in the use of this agent in routine clinical practice. The aim of the present study was to examine the patterns of docetaxel use in routine clinical practice at our institution and to compare them with docetaxel use in the TAX 327 clinical trial. | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20404974 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20404974 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:20404974 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20404974 | pubmed:issn | 1198-0052 | lld:pubmed |
| pubmed-article:20404974 | pubmed:author | pubmed-author:MooreMM | lld:pubmed |
| pubmed-article:20404974 | pubmed:author | pubmed-author:WangLL | lld:pubmed |
| pubmed-article:20404974 | pubmed:author | pubmed-author:SridharS SSS | lld:pubmed |
| pubmed-article:20404974 | pubmed:author | pubmed-author:ChenQ TQT | lld:pubmed |
| pubmed-article:20404974 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20404974 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:20404974 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20404974 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20404974 | pubmed:pagination | 24-9 | lld:pubmed |
| pubmed-article:20404974 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20404974 | pubmed:articleTitle | A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. | lld:pubmed |
| pubmed-article:20404974 | pubmed:affiliation | Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON. | lld:pubmed |
| pubmed-article:20404974 | pubmed:publicationType | Journal Article | lld:pubmed |
